Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 plus DC-CIK in Advanced NSCLC
NCT03360630Phase 2Completed
- Sponsor
- Capital Medical University
- Start
- Nov 2016
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of dendritic cell vaccine + cytokine-induced killer cells in non-small cell lung cancer (NSCLC), sponsored by Capital Medical University. Started Nov 2016; status: completed.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03360630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360630.